Targeted Genetics to Present at SG Cowen Annual Health Care Conference
04 3월 2004 - 11:00PM
PR Newswire (US)
Targeted Genetics to Present at SG Cowen Annual Health Care
Conference SEATTLE, March 4 /PRNewswire-FirstCall/ -- H. Stewart
Parker, President and Chief Executive Officer of Targeted Genetics
Corporation , will speak at the SG Cowen 24th Annual Health Care
Conference on Tuesday, March 9, 2004. Ms. Parker will provide a
corporate overview, along with highlights from the Company's AIDS
vaccine, cystic fibrosis and arthritis programs at two different
times during the conference. Presentation details are as follows:
What: SG Cowen Annual Health Care Conference Where: Boston, MA The
Boston Marriott Copley Place Hotel When: Tuesday, March 9, 2004
3:30 - 4:15 p.m. EST 4:30 - 5:15 p.m. EST A live and archived
version of Ms. Parker's presentation will be available at
http://www.targetedgenetics.com/. Targeted Genetics develops
gene-based products for preventing and treating acquired and
inherited diseases. The Company has two clinical product
development programs, targeting cystic fibrosis and AIDS
prophylaxis and expects to initiate clinical testing of its
arthritis product candidate in the first quarter of 2004. The
Company also has a promising pipeline of product candidates focused
on hemophilia and cancer and a broad platform of gene delivery
technologies, as well as a promising body of technology for
cellular therapy under development by its subsidiary company,
CellExSys. For more information about the Company visit its website
at http://www.targetedgenetics.com/. NOTE: This release contains
forward-looking statements regarding our product pipeline and
clinical trials. These statements involve current expectations,
forecasts of future events and other statements that are not
historical facts. Inaccurate assumptions and known and unknown
risks and uncertainties can affect the accuracy of forward-looking
statements. Actual results could differ materially from
expectations for a number of reasons, including our failure to make
progress with our clinical trials, our failure to obtain positive
results from our preclinical programs, our failure to obtain
regulatory approval and the other risks described in the section
entitled "Factors Affecting Our Operating Results, Our Businessand
Our Stock Price" in our report on Form 10-Q for the quarter ended
September 30, 2003. You should not rely unduly on these
forward-looking statements, which apply only as of the date of this
release. We undertake no duty to publicly announce or report
revisions to these statements as new information becomes available
that may change our expectations. DATASOURCE: Targeted Genetics
Corporation CONTACT: Courtney Self of Targeted Genetics
Corporation, +1-206-521-7392 Web site:
http://www.targetedgenetics.com/
Copyright
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024